New Delhi, Sept 15: Mosquirix,
the only malaria vaccine to receive approval from the World Health Organization
(WHO), has shown modest efficacy against symptomatic malaria, which has triggered
the need for developing more effective malaria vaccines.
A recent phase 2 clinical trial conducted in Burkina Faso examined the
efficacy of the novel malaria vaccine candidate R21/ Matrix-M in children aged
5–17 months after three primary vaccine doses and a fourth booster shot.
The study found that the R21/Matrix-M vaccine candidate demonstrated
high efficacy (75%) against first and multiple episodes of symptomatic malaria
over the 24-month follow-up period after the administration of three primary
doses, Medical News Today reports.
Results from a clinical trial published in 2021 showed that
the R21/Matrix-M malaria vaccine candidate had high efficacy against
symptomatic malaria in children aged 5–17 months at 12 months following a
primary three-dose regimen.
New findings from the same clinical trial recently published in The
Lancet indicate that the administration of the booster shot of
R21/Matrix-M 12 months after the primary three-dose regimen helped maintain a
high efficacy against symptomatic malaria over the 12-month follow-up period
after the booster dose.
Dr. Azra Ghani, a professor at Imperial College London, who was not
involved in this research has commented that “despite ongoing efforts to reduce
the malaria burden — including through the provision of insecticide-treated bed
nets, improvement in access to treatment, and chemoprevention — malaria
continues to pose an unacceptably high burden, resulting in over 640,000 deaths
globally each year, mostly in young children in Africa.”
“These new results demonstrating high sustained efficacy of the R21
malaria vaccine over a 2-year period are therefore very welcome,” says Dr.